19:55 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure Cell culture and mouse studies suggest GHRH receptor agonists could help treat heart failure. In a rat cardiomyoblast cell line, primary rat ventricular myocytes and human induced pluripotent stem (iPS) cell-derived cardiomyocyte...
17:37 , Jan 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Retinoblastoma In vitro studies suggest antagonizing the GHRH receptor could help treat retinoblastoma. In a human retinoblastoma cell line, GHRH receptor expression was higher than in normal eye-derived cell lines. In the retinoblastoma cell line...
08:00 , Feb 11, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Growth hormone-releasing hormone (GHRH) receptor

Endocrine/metabolic disease INDICATION: Dyslipidemia Rat studies suggest GHRH receptor antagonists could help treat dyslipidemia associated with Type I diabetes. A rat model of Type I diabetes had higher GHRH receptor levels in the small intestine than normal...
08:00 , Nov 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Growth hormone-releasing hormone (GHRH) receptor

Endocrine/metabolic disease INDICATION: Diabetes In vitro and mouse studies suggest GHRH receptor agonists could improve engraftment of islet cell transplant to treat diabetes. In a rat pancreatic β cell line, the GHRH receptor agonist MR-409 increased cell...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Company News

Biscayne Pharmaceuticals, Insero Health deal

Biscayne merged with Insero on June 30. Biscayne is developing growth hormone-releasing hormone (GHRH) receptor analogs. Biscayne’s lead compound is BIS-001, a selective acetylcholinesterace (AChE) inhibitor that has completed a Phase I trial in...
07:00 , Sep 8, 2014 |  BioCentury  |  Emerging Company Profile

Biscayne: Antagonizing cancer

Biscayne Pharmaceuticals Inc. is developing peptide antagonists that target three different cancer growth pathways and could provide an alternative for prostate cancer patients who have become insensitive to hormone-based therapies. The company plans to enter...
07:00 , Aug 21, 2014 |  BC Innovations  |  Cover Story

Fat chance for cancer cachexia

With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies could be better off turning to the cause of the wasting disease rather than targeting its symptoms....
07:00 , Jun 9, 2014 |  BC Week In Review  |  Company News

Inovio, Plumbline Life Sciences Inc. deal

Inovio's 90%-owned subsidiary, VGX Animal Health Inc., will sell its animal health assets to animal health company Plumbline. VGX will receive $2 million in cash, plus 20% equity ownership in Plumbline. The assets being transferred...
01:56 , Nov 19, 2013 |  BC Extra  |  Financial News

Aileron raises $30 million series E

Aileron Therapeutics Inc. (Cambridge, Mass.) raised $30 million in a series E round. All of the company's existing investors participated, including Apple Tree Partners; Roche Venture Fund; Novartis Venture Funds; Lilly Ventures; SR One; and...
07:00 , May 13, 2013 |  BC Week In Review  |  Clinical News

ALRN-5281: Phase I data

Data from 32 evaluable healthy adults in a single-blind, placebo-controlled, U.S. Phase I trial showed that single ascending-doses of subcutaneous ALRN-5281 led to no serious adverse events, no dose-limiting findings or tolerability issues leading to...